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Objective
This study was done to define the extent of disease and eval-
uate the effect of staging and treatment variables on progres-
sion-free survival in patients with differentiated thyroid carci-
noma who were less than 21 years of age at diagnosis.
Summary Background Data
Differentiated thyroid cancer in young patients is associated
with early regional lymph node involvement and distant paren-
chymal metastases. Despite this, the overall long-term survival
rate is greater than 90%, which suggests that biologic rather
than treatment factors have a greater effect on outcome.
Methods
Variables analyzed for their impact on progression-free sur-
vival in a multi-institutional cohort of 329 patients included
age, antecedent thyroid irradiation, extrathyroidal tumor ex-
tension, size, nodal involvement, distant metastases, tech-
nique of thyroid surgery and lymphatic dissection, initial treat-
ment with 131 Iodine, residual cervical disease, and
histopathologic subtype. Surgical complications were corre-
lated with the specific procedures completed on the thyroid
gland or cervical lymphatics.
Results
The overall progression-free survival rate was 67% (95%, Cl:
61 %-73%) at 10 years with 2 disease-related deaths. Re-
gional lymph node and distant metastases were present in
74% and 25% of patients, respectively. Progression-free sur-
vival was less in younger patients (p = 0.009) and those with
residual cervical disease after thyroid surgery (p = 0.001).
Permanent hypocalcemia was more frequent after total or
subtotal thyroidectomy (p = 0.001) while wound complica-
tions increased after radical neck dissections (p < 0.00001).
Conclusions
The progression-free survival rate was better after a complete
resection and in older patients. Progression-free survival rate
was the same after lobectomy or more extensive thyroid pro-
cedures, but comparison was confounded by the increased
use of total or subtotal thyroidectomy in patients with ad-
vanced disease. The risk of permanent hypocalcemia in-
creased when total or subtotal thyroidectomy was done. Thy-
roid lobectomy alone may be appropriate for patients with
small localized lesions while total or subtotal thyroidectomy
should be considered for more extensive tumors.
A paradox exists with respect to the clinical course of
children with differentiated thyroid carcinomas: although
thyroid cancer often presents with extensive disease, it is
rarely fatal. This fact has generated enduring controversy
over the optimal surgical management of children with
thyroid tumors. This controversy also exists in adult patients
where the value of extensive thyroid surgery without regard
to staging parameters has been questioned. 1-10 Some arti-
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cles have favored an aggressive surgical approach for chil-
dren, utilizing total or near total thyroidectomy, because of
the propensity of differentiated thyroid cancer to dissemi-
nate to lymph nodes or distant sites in this age group.""2
Conversely, other investigators have advocated a more con-
servative surgical management technique employing thy-
roid lobectomy. This is based on the observation that the
mortality rate for differentiated thyroid cancer in children is
remarkably low,' 3-16 whereas serious operative complica-
tions are reduced with less extensive surgery.'7-21
The following multi-institutional analysis was completed
to: 1) develop a clinical profile of patients in this age group
who had differentiated thyroid cancer, 2) define variables
predictive of progression-free survival, and 3) correlate the




This analysis includes patients from the institutions listed
in Appendix 1. Patient lists were obtained by individual
institutional review of hospital archives, registries, and da-
tabases in an attempt to capture consecutively treated dif-
ferentiated patients with thyroid cancer at each institution.
Patients included in this study were diagnosed from January
1, 1946 through August 8, 1991, but there was some vari-
ation in intervals between different participating centers.
Data were obtained from the cancer registries, hospital
charts, operative reports, and office notes from each con-
tributing center. Pathologic review was carried out at each
participating institution and cases of medullary and anaplas-
tic carcinomas were excluded from analysis. The 15 partic-
ipating centers are comprised chiefly of children's hospitals
and cancer centers (Appendix 1) and all are members of the
Children's Cancer Group (CCG). All patients had at least a
1-year follow-up from initial treatment (median = 11.3
years). The project was coordinated by the Surgical Disci-
pline Committee of the CCG. Data were entered on a
standardized questionnaire by a surgeon at each institution.
The questionnaire was three and one-half pages in length,
and it was filled out by the institutional CCG surgeon. It
contained entries for demographic data, history of radiation
exposure, staging data, treatment, complications, 13'Iodine
treatment, and patient status. In addition, specific categories
were included to specify disease progression and time of
progression. Staging variables included primary tumor size,
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extrathyroidal extension, regional nodal involvement, and
distant metastases. Data concerning tumor size were usually
taken from the pathology report, although a clinical mea-
surement taken before or at the time of surgery was used if
the pathologic measurement was not available. Distant me-
tastases were identified most commonly by preoperative
plain chest radiographs. These questionnaires were col-
lected, computerized, and analyzed. A cohort of 365 pa-
tients, 21 years of age or younger at the time of diagnosis,
with histologically confirmed differentiated thyroid carci-
nomas was identified. Of this group, 329 (90%) patients had
sufficient data and follow-up (>1 year) for statistical anal-
ysis, and these patients are the basis of this report.
Variables
Because there were few deaths, the endpoint of analysis
was disease progression. Disease progression was chosen
because many patients, (25%) had metastatic disease at
diagnosis. Because lung abnormalities can persist for a long
period of time and may not represent a persistent tumor, the
time of complete response in these patients could not be
determined accurately. Consequently, disease progression
was used as the dependent variable in analysis. Disease
progression included clinically recognized local recurrence
within the thyroid bed or regional lymph nodes after com-
plete removal, progression in the thyroid bed or regional
nodes after incomplete surgical resection, and the develop-
ment or progression of metastatic disease (lung, bone, etc.).
Independent variables assessed for their influence on dis-
ease progression included age, antecedent thyroid irradia-
tion, the presence of extrathyroidal extension of the primary
tumor into surrounding tissues, primary tumor size, regional
lymph node involvement, presence of distant metastases at
diagnosis, the technique of initial thyroid surgery, the tech-
nique of lymph node dissection, the existence of positive
gross or microscopic margins, the use of 131 I in initial
treatment of the thyroid bed, and histopathologic subtype.
Extrathyroidal extension was defined by local infiltration of
the primary thyroid tumor beyond the glandular capsule and
included all cases of local invasion of surrounding muscles,
esophagus, or trachea. Usually this was based on the pa-
thology report, but surgical assessment also was included if
the findings were obvious. Regional lymph node involve-
ment included nodal metastases to the jugulodigastric and
recurrent laryngeal (peritracheal) chains in the neck or an-
terior-superior mediastinal nodes. Nodal involvement was
determined by histologic examination of resected lymph
nodes. Lymph node dissections were completed when in-
volvement was documented by biopsy or strongly suspected
clinically and not as a prophylactic procedure. Distant me-
tastases included parenchymal metastases to the lung in the
vast majority of cases. Metastases to the brain, bone or other
sites were seen in only a few patients. Metastatic disease
was most commonly diagnosed by radiographic imaging
studies. Usually, pulmonary metastases were identified by
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Table 1. PATIENT CHARACTERISTICS
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Table lists numbers of patients positive and negative for staging varables, along with percentages. The last column, inevaluable, gives the number of patients for whom
the status of that particular variable could not be accurately determined.
plain chest radiographs or computerized tomography, and
biopsies were not done.
Initial thyroid surgery was divided into four groups: a)
total thyroidectomy, b) subtotal thyroidectomy, c) lobec-
tomy, and d) lesser procedures, such as a biopsy. Nodal
dissection also was divided into four categories: a) radical
neck dissection, b) modified neck dissection, c) multiple
local excisions (berry picking), and d) no lymphatic surgery
or single lymph node biopsy. Determination of a residual
tumor in the neck after primary surgery was based on the
operative note and pathology reports.
The treatment morbidity rate was assessed by determin-
ing the association of significant wound complications, per-
manent recurrent nerve paralysis, permanent hypocalcemia
with the extent of thyroid surgery or nodal dissection.
Wound complications included: serious hemorrhage or he-
matoma (requiring reexploration), infection, pneumothorax,
and requirement for tracheostomy. Nonrecurrent nerve in-
juries like accessory or facial nerve dysfunction, or Homer's
syndrome first noted after surgery also were included under
wound complication. Permanent hypoparathyroidism was
presumed if there was a postoperative need for calcium
supplements and/or vitamin D replacement for 6 months
after surgery and was continued until the last follow-up.
Permanent recurrent nerve paralysis was defined by change
in voice and/or indirect laryngoscopic evidence of vocal
cord paralysis that lasted at least 6 months after the primary
thyroid surgery. This included cases of operative sacrifice of
the recurrent nerve. Temporary recurrent nerve injury or
hypoparathyroidism resolved within 6 months of surgery.
Statistical Methods
This was an exploratory analysis, and observations drawn
from this study are intended to be hypothesis generating.
The probability estimates of time to progression were ob-
tained from the product-limit (Kaplan-Meier) method, and
differences between progression patterns within a covariate
were evaluated by the log-rank statistic.22 Multiple factors
were evaluated using the stratified log-rank statistic. Fish-
er's exact test was used to assess the association between
surgical technique and the morbidity rate.
RESULTS
Patient Characteristics
The median age at diagnosis was 15.2 years (range:
0.4-20.8; mean, 14.6 + 3.9 years). The male:female ratio
was 80:249 (76% female). The median follow-up time was
11.3 years (range: 1-41 years). Two-hundred forty-five
(74.5%) patients were followed for 5 years or more. More
than 90% of the patients were white.
Staging and Histology
Table 1 lists pertinent staging variables and shows the
number of patients inevaluable for each parameter. The
distribution by histologic subtype was 148 papillary-follic-
ular (45%), 149 papillary (45%), and 32 follicular (10%).
The median maximal diameter of the primary tumor in the
thyroid gland was 2.5 cm ( range: 0.4 cm-lI cm; mean=
2.9 cm + 1.7 cm). Of the 83 patients who had distant
metastases, 77 (93%) had dissemination to lungs alone, 4 to
lung and bone (5%), and 2 patients had brain metastases
(2%).
Treatment
Total thyroidectomy, subtotal thyroidectomy, thyroid lo-
bectomy, and lesser procedures were done in 178 (54%), 55
(17%), 82 (25%), and 14 (4%) of patients, respectively, in
this study (Table 2). Radical neck dissection, modified neck
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Table 2. TREATMENT, EXTENT OF DISEASE, AND OUTCOME
Nodes Number Progressing









Table 2 correlates rates of disease progression with the type of primary thyroid surgery done and history of prior neck irradiation, histopathologic type, regional lymph node
involvement, primary tumor size, and distant metastases at diagnosis.
* Papillary/papillary-follicular/follicular.
HxRTX, pror history of head and neck irradiation.
lymphatic surgery or simple biopsies were completed on 70
(21%), 115 (35%), 70 (21%), and 74 (22%) patients. A
complete primary resection was performed in 279 (85%)
patients, while gross residual disease was left in 21 patients
(6%). Microscopic margins were positive in 22 patients
(7%). l3lIodine was administered as part of the initial
treatment in 143 (43%) patients. I131 was administered to
treat the thyroid bed alone in 60 (18%) patients, both distant
metastases and the thyroid bed in 74 (22%) patients, and to
treat distant metastases alone in nine (3%) patients.
Complications
One hundred thirty-six patients developed postoperative hy-
pocalcemia which was temporary in 97 (29%) and permanent
in 39 patients (12%) (Table 3). The greatest incidence of
hypocalcemia was observed with total thyroidectomy. Postop-
erative recurrent nerve dysfunctions were reported in 46 cases.
This was temporary in 39 patients (12%) and permanent in 7
patients (2%). There were 56 additional surgical complications
of which 33 were considered major. These major complica-
tions included 15 tracheostomies, 6 cases of extensive wound
necrosis or severe infection, 3 cases of Homer's syndrome, 2
cases of spinal accessory nerve injuries, 2 cases of facial nerve
injuries (marginal mandibular branch), 2 cases of postoperative
pneumothorax, and 1 case each of severe postoperative hem-
orrhage requiring reexploration, vagus nerve, and superior
laryngeal nerve injury. The 23 minor wound complications
included 9 cases of hypertrophic scarring, 7 patients with
significant postoperative seromas or serous wound drainage, 2
cases of temporary dysphagia, 2 cases of significant facial
edema, and 1 case each of serous otitis media, delayed wound
healing (minor), and significant wound erythema. Major and
minor complications, along with the technique of primary
thyroid surgery, are listed in Table 3.
Permanent (p = 0.001) hypocalcemia was correlated with
the use of either subtotal or total thyroidectomy, while
major wound complications were associated with the use of
radical neck dissections (p < 0.00001) but not the type of
thyroid surgery. The technique of primary thyroid surgery
or lymphatic dissection did not correlate with permanent
recurrent nerve dysfunction.
Survival and Progression-free Survival
Disease progression is correlated with the primary thy-
roid procedure and other variables of interest in Table 2.
Disease progression, including local recurrence in patients
with an initial complete resection, occurred in 106 (32%)
patients, and the overall progression-free survival rate is
Table 3. TECHNIQUE OF THYROID RESECTION AND COMPLICATIONS
Primary Thyroid Surgery
Complications Biopsy (%) Lobectomy (%) STT (%) TT (%)
N
Recurrent n. palsy (temporary)

































Table 3 lists the extent of thyroid surgery with specific complications. Percentages were obtained by dividing each number in a column by the total number (N) for that
column.
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0 All Patients ( 329 Pts. 223 censored)
0 10 20 30 40 50
Years
Figure 1. Figure 1 is a Kaplan-Meier curve of overall progression-free
survival for patients in this study.
depicted in Figure 1. Overall progression-free survival was
67% (95%; CI: 61%-73%) at 10 years after diagnosis and
60% (95%; CI:54%-76%) at 20 years after diagnosis. The
anatomic sites of disease progression were cervical lymph
nodes in 71 patients, lungs in 16 (6 of these also had
progression in cervical nodes), the contralateral thyroid lobe
or thyroid bed in 13, bone (tibia, skull, and costochondral
junction) in 4, and the spinal cord and base of tongue in 1
each.
In 60 patients without distant metastases, 31lIodine was
administered as part of initial therapy. In this group, 49 were
treated after complete resections of the primary tumor with
no residual disease, whereas 11 had residual thyroid cancer
in the primary site after a resection. There were 18 instances
of disease progression in this group (30%). Fourteen of
these consisted of relapse in the cervical and two in the
mediastinal lymph nodes. The other two patients recurred in
lungs and the contralateral thyroid lobe, respectively. Of the
49 patients treated with 13'I after complete resection, 12
patients relapsed. Of the 11 patients who were administered
'3'Iodine with residual cervical disease after surgery, 6
developed disease progression.
Predictors of Progression-free Survival
An increased risk of disease progression was observed in
younger patients (p = 0.009) (Figure 2) and those with
residual cervical disease after definitive thyroidectomy (p =
0.001) (Fig. 3). Unfortunately, younger patients also were
more likely to have residual cervical disease precluding
determination of an independent effect of either variable on
progression-free survival.
In contrast, primary tumor size, extrathyroidal extension
of tumor, regional node involvement, distant metastases
(Figure 4), type of thyroid surgery (Figure 5) or type of
lymphatic dissection, use of 13lIodine in initial therapy, and
history of antecedent thyroid irradiation were not determi-
nants of progression-free survival (Table 4). In summary,
after controlling for either age or residual disease no other
factor was predictive of progression-free survival.
Age at Diagnosis
10 20 30 40 50
Years
Figure 2. Figure 2 shows an association between progression-free
survival and age at diagnosis for patients in this study. Younger patients
were more likely to develop disease progression.
We found that more intensively treated patients also had
more extensive disease. There were strong correlations be-
tween the use of total and subtotal thyroidectomy and the
presence of extrathyroidal extension, and regional or distant
metastases as summarized in Table 5.
Disease-Related Deaths
There were 8 deaths out of a total of 329 patients of
which 2 were disease related. One of these patients was a
girl diagnosed at 11 years of age who had a 6-month history
of a stable, asymptomatic mass in the right neck. A maternal
aunt suffered from an unknown thyroid problem, and there
was no history of antecedent cervical irradiation. A total
thyroidectomy and bilateral modified neck dissections were
performed. After surgery, a tracheostomy was required be-
cause of cervical swelling, but the patient was subsequently
discharged in good condition. Histologic analysis revealed a
papillary thyroid carcinoma with involvement of cervical
nodes, and 1311 treatments were given as part of initial
therapy. Radioiodine scans performed 4 and 5 years after
the initial treatment showed no evidence of metastases or
local recurrence. However, repeat 1311 treatments were re-








o 0 No Residual (279 Pts. 196 censored)
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0.1 p = 0.001
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Figure 3. Figure 3 compares progression-free survival for patients with
and without residual cervical disease after the primary procedure on the
thyroid gland.
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lure 4. Figure 4 compares progression-free survival in patients with Initial 131Iodine treatment
J without distant metastases at diagnosis. Outcomes did not differ Pathologic subtype
iouqh treatment was more intensive in patients with metastatic dis- History of cervical irradiation
Table 4 lists the results of univariate analysis. Each variable was analyzed for its
effect on progression-free survival.
therapy. A total of 300 mCi were administered during the
patient's life because of persistent pulmonary disease. Eigh-
teen years after diagnosis the patient died of pulmonary
failure and had active disease.
The second patient was 15 years of age and had a
6-month history of a neck mass and swelling. She had no
history of neck irradiation, and the only significant family
history was a grandmother with goiter. On examination, a
5-centimeter subdigastric mass along with multiple smaller
neck nodules bilaterally was found. Bone scan and chest
x-ray showed no evidence of metastatic disease. A total
thyroidectomy and right radical neck dissection were done
and histologic examination revealed papillary-follicular car-
cinoma with six metastatic nodes. She was maintained on
thyroid replacement. One year after the primary surgery,
750 cGy of external beam radiation was administered to
treat keloid formation in the cervical wound. A recurrent
papillary-follicular carcinoma was noted on a biopsy of
enlarged supraclavicular lymph nodes, while a chest x-ray
showed bilateral pulmonary metastases 2 years after the
primary surgery. She received 150 mCi of 31lIodine and had
improvement in the lung metastases. However, an addi-
Type of Primary Thyroid Surgery
o Lobectomy 82 Pts. 55 censored)
* Total or Near Total Thyroidectomy (232 Pts. 164 censored)
p=0.746
0 10 20 30 40 50
Years
Figure 5. Compares progression-free survival in patients undergoing
biopsy or thyroid lobectomy to those treated by total or subtotal thy-
roidectomy. Patients with more extensive tumors were more frequently
treated by total or subtotal thyroidectomy.
tional 200 mCi was required 2 years later because of radio-
graphic evidence of progression of the lung disease. Sixteen
years after diagnosis, she had skull metastases that pro-
gressed despite treatment with another 150 mCi of 131I, and
external beam radiotherapy (3500cGy) was required for
control. She subsequently developed bony metastases in
multiple sites and died with persistent pulmonary and skel-
etal metastases 21 years after diagnosis.
DISCUSSION
Our aim with this study was to develop a profile of
differentiated thyroid carcinoma in this age group and to
identify determinants of disease progression. We used pro-
gression-free survival as an endpoint because the survival
rate was almost 100% as reported in the literature. 23-33
Because patients with distant metastases (e.g., pulmonary)
may have abnormalities on imaging studies for long periods
of time after treatment, the date of complete response, and
the time of recurrence is uncertain. Using disease progres-
sion rather than recurrence allowed patients with metastases
to be included in the analysis.
It is apparent from Tables 1 and 2 that differentiated
thyroid cancer in this age group is an aggressive tumor as
measured by its ability to penetrate the thyroid capsule and
metastasize to regional lymph nodes or distant sites. The
observed proportion of patients with lymphatic involvement
or distant metastases at diagnosis, 74% and 25% respec-
tively, is consistent with other reports. It is tempting to
assume that this increased biologic virulence requires more
radical surgery or aggressive administration of 1311.
Table 3 correlates the number of patients suffering a
surgical complication with the technique of primary thyroid
surgery. There was a strong correlation between use of total
or subtotal thyroidectomy and the development of perma-
nent hypocalcemia. Not shown is a similar correlation with
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Table 5. CORRELATION OF TREATMENT WITH EXTENT OF DISEASE
Proportion Treated with Subtotal
Extent of Disease or Total Thyroidectomy Proportion Treated with 1311
Extrathyroidal extension
Regional nodes positive







Table 5 shows the association between extent of disease at diagnosis and type of treatment. Patients with more extensive disease were more likely to be treated by total
or subtotal thyroidectomy and to receive 131 lodine.
major wound complications. These findings are consistent
with reported complication rates from other childhood se-
ries of differentiated thyroid cancer. Presently, radical neck
dissection should not be used in treatment of this disease
except under unusual circumstances. Also, our initial incli-
nation to use total or subtotal thyroidectomy must be tem-
pered because of its association with an increased risk of
permanent hypocalcemia.
Age at diagnosis and the presence of residual gross or
microscopic disease in the neck were the only determinants of
progression-free survival (Table 4). We did not find a differ-
ence in progression-free survival between patients with and
without extracapsular extension, lymph node involvement, and
distant metastases. Unfortunately, the use of more extensive
thyroid surgeries, and therapeutic radioiodine was correlated
with the extent of disease at diagnosis, as listed in Table 5. Of
patients initially treated with thyroid lobectomy, 59% had
regional nodal involvement whereas 2% had distant metasta-
ses. In contrast, 80% of the patients who were treated by
subtotal or total thyroidectomy had involved regional lymph
nodes. More than 30% of the 50% of these patients had distant
metastases. Also, there was strong correlation between the use
of initial 131I therapy and the presence of extrathyroidal exten-
sion, and lymph node or distant metastases at diagnosis. Thus,
patients with more extensive thyroid tumors, heavier involve-
ment of cervical lymphatics, or those with distant metastases
had an increased likelihood of being treated with total or
subtotal thyroidectomy. This finding confounds a direct com-
parative analysis of thyroid lobectomy with total or subtotal
thyroidectomy.
It is possible that progression-free survival in patients with
extensive disease is the same as for those with more localized
tumors because of the greater use of total or subtotal thyroid-
ectomy or addition of radioiodine therapy. Alternatively, un-
known factors in the basic biology of differentiated thyroid
carcinoma arising in this age group might determine the out-
come despite treatment. This latter explanation has been sup-
ported based on 1) the mortality rate from disease was almost
zero despite greater rates of regional node involvement and
distant metastases; 2) there are reports from the literature of
prolonged quiescence of pulmonary metastases without treat-
ment; and 3) some authors note an improved outcome in
younger patients who had metastases compared with older
ones that develop them later.34-36 It is possible that unknown
biological factors and not therapy, are the final deternminant of
outcome in this age group. The problem of identifying the
"best therapy" is not wholly academic, because we have
already noted an increased complication rate with total and
subtotal thyroidectomy. Also, there are reports of early com-
plications and possible late effects from radioiodine therapy.
Despite limitations, our analysis suggests some guide-
lines for the treatment of differentiated thyroid cancer pa-
tients in this age group. First, staging each pediatric and
adolescent patient with suspected thyroid cancer is crucially
important. This involves a thorough head and neck exami-
nation that ideally includes indirect laryngoscopy to learn
vocal cord function before surgery. Attention should be
directed to determination of the size and location of the
thyroid nodule, clinical evidence of fixation, and a careful
mapping of abnormal lymph nodes. A preoperative chest
x-ray or computerized axial tomography of the chest also
should be performed. Multifocal thyroid nodules should be
recorded. At exploration, the surgeon should inspect and
palpate both thyroid lobes and inspect the lymph nodes in
the jugulodigastric chain and the packet of nodes running
along the recurrent laryngeal nerve in the tracheoesophageal
groove. Complete surgical removal of cervical disease
should be done. This might require lobectomy for small and
isolated lesions or total thyroidectomy for a multifocal large
and invasive carcinoma. Total or subtotal thyroidectomy
should be done if adjuvant radioiodine treatments are
planned. Patients with distant metastases, extensive lymph
node involvement, or invasive tumors in whom radioiodine
therapy is presently a standard adjuvant treatment should
undergo complete thyroid removal. Routine use of total or
subtotal thyroidectomy did not improve outcome in patients
with localized tumors and is associated with an increased
risk of complications. In summary, small lesions completely
resected by lobectomy may be best treated by simple post
update observation and thyroid suppression. More extensive
lesions may require a combination of total or subtotal thy-
roidectomy.
Finally, the underlying biologic mechanisms that predict
advanced stage at presentation, coupled with a greater re-
lapse but paradoxically a low mortality rate, remain ob-
scure. In a cytogenetic analysis, Hermann et al.37 suggested
that lOq abnormalities are more common in papillary tu-
mors, whereas abnormalities of chromosome three were
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more frequently noted in follicular cancer. Another study
identified expression of the p21 ras protein as a prognostic
factor in papillary cancer.38 Recently, mutations in the ret
protooncogene have been implicated in the development of
thyroid tumors, including medullary and papillary thyroid
carcinomas. Germ line mutations of the ret protooncogene
were identified in multiple endocrine neoplasia (men) types
2a and 2b that share the clinical feature of medullary thyroid
carcinoma and pheochromocytoma. Also, somatic rear-
rangements of the ret protooncogene frequently were de-
tected in the papillary thyroid carcinomas in adult Europe-
ans, and the same rearrangements were observed in
approximately 60% of papillary carcinomas from children
inhabiting areas contaminated by the Chernobyl accident.
This suggests that ret rearrangements may be induced by
radiation exposure.39-41 These varied observations repre-
sent a beginning in our understanding of the pathogenesis of
thyroid cancer. Establishment of a centralized thyroid tumor
bank would facilitate similar investigations and might trans-
late into better treatments.
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